Lithium Ion

Lithium Ion

SCHEMBL930614

CC(C)c1ccc(C(O[Al-](OC(c2ccc(C(C)C)cc2)(C(F)(F)F)C(F)(F)F)(OC(c2ccc(C(C)C)cc2)(C(F)(F)F)C(F)(F)F)OC(c2ccc(C(C)C)cc2)(C(F)(F)F)C(F)(F)F)(C(F)(F)F)C(F)(F)F)cc1.[Li+]

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 2/20 0.39
PDE2A O00408 2/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
HIF1A Q16665 1/20 0.37
ALDH1A1 P00352 1/20 0.32
IDO1 P14902 2/20 0.32
KIF11 P52732 1/20 0.31
TYR P14679 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22242853 0.78 PTPN5 (0.47) PTPN5PDE2ACYP2D6CYP2C9HIF1A
Lithium Ion SCHEMBL930658 0.77 TSHR (0.44) ALDH1A1IDO1KIF11
SCHEMBL16586837 0.74 TSHR (0.46) ALDH1A1IDO1KIF11
SCHEMBL16105865 0.70 ESR1 (0.50) PTPN5PDE2ACYP2D6CYP2C9HIF1A
SCHEMBL14706850 0.70 PTPN5 (0.47) PTPN5PDE2ACYP2D6CYP2C9HIF1A
SCHEMBL24408943 0.70 PTPN5 (0.47) PTPN5PDE2ACYP2D6CYP2C9HIF1A
SCHEMBL84043 0.69 PDE2A (0.53) PTPN5PDE2ACYP2D6CYP2C9HIF1A
SCHEMBL12887210 0.69 PDE2A (0.48) PTPN5PDE2ACYP2D6CYP2C9HIF1A
SCHEMBL10189311 0.69 PDE2A (0.70) PTPN5PDE2ACYP2D6CYP2C9HIF1A
SCHEMBL14997533 0.69 PDE2A (0.48) PTPN5PDE2ACYP2D6CYP2C9HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868107-B2 Process for producing cycloolefin addition polymer, catalyst for addition polymerization of cycloolefin, and transition metal compound ZEON CORPORATION (JP) 2011-01-11 US disclosed
US-20090124769-A1 e.g. copolymerization of dicyclopentadiene with ethylene in presence of (t-butylamide)dimethyl-9-[octamethyloctahydrobenzofluorenyl]silanetitanium dimethyl(tetrahydrofuran) complex catalyst; exhibits high activity for both of addition homopolymerization of a cycloolefin and copolymerization with olefin ZEON CORPORATION (JP) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124769-A1 e.g. copolymerization of dicyclopentadiene with ethylene in presence of (t-butylamide)dimethyl-9-[octamethyloctahydrobenzofluorenyl]silanetitanium dimethyl(tetrahydrofuran) complex catalyst; exhibits high activity for both of addition homopolymerization of a cycloolefin and copolymerization with olefin ETFB, DDT, ETFA PTPN5 4429/4885PDE2A 4752/4885CYP2D6 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.